Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZT002 in overweight or obesity
NCT07020884Phase 2Completed
- Sponsor
- QL Biopharm
- Start
- Aug 2024
- Primary completion
- May 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of zovaglutide in obesity (5 arms), sponsored by QL Biopharm. Primary endpoint: Percentage Change from Baseline in Body Weight at 24 weeks. Started Aug 2024; status: completed.
02
Drugs
zovaglutide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07020884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07020884.